Howard G. Welgus - 01 Jul 2024 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Director
Signature
/s/ David Topper, as Attorney-in-Fact for Howard G. Welgus
Issuer symbol
ARQT
Transactions as of
01 Jul 2024
Net transactions value
-$76,335
Form type
4
Filing time
02 Jul 2024, 19:13:16 UTC
Previous filing
18 Jun 2024
Next filing
05 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Options Exercise $9,547 +5,681 +3.2% $1.68* 186,020 01 Jul 2024 Direct F1
transaction ARQT Common Stock Options Exercise $7,259 +4,319 +2.3% $1.68* 190,339 01 Jul 2024 Direct F1
transaction ARQT Common Stock Sale $93,141 -10,000 -5.3% $9.31 180,339 01 Jul 2024 Direct
holding ARQT Common Stock 24,991 01 Jul 2024 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Options Exercise $0 -5,681 -100% $0.000000* 0 01 Jul 2024 Common Stock 5,681 $1.68 Direct F1, F3
transaction ARQT Stock Option (right to buy) Options Exercise $0 -4,319 -40% $0.000000 6,614 01 Jul 2024 Common Stock 4,319 $1.68 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F3 This option is fully vested.